[HTML][HTML] Smad7 abrogates transforming growth factor-β1-mediated growth inhibition in COLO-357 cells through functional inactivation of the retinoblastoma protein
NB Arnold, M Korc - Journal of Biological Chemistry, 2005 - ASBMB
Smad7 is overexpressed in 50% of human pancreatic cancers. COLO-357 pancreatic
cancer cells engineered to overexpress Smad7 are resistant to the actions of transforming
growth factor-β1 (TGF-β1) with respect to growth inhibition and cisplatin-induced apoptosis
but not with respect to modulation of gene expression. To delineate the mechanisms
underlying these divergent consequences of Smad7 overexpression, we studied the effects
of Smad7 on TGF-β1-dependent signaling pathways and cell cycle regulating proteins. TGF …
cancer cells engineered to overexpress Smad7 are resistant to the actions of transforming
growth factor-β1 (TGF-β1) with respect to growth inhibition and cisplatin-induced apoptosis
but not with respect to modulation of gene expression. To delineate the mechanisms
underlying these divergent consequences of Smad7 overexpression, we studied the effects
of Smad7 on TGF-β1-dependent signaling pathways and cell cycle regulating proteins. TGF …